Klaria Pharma’s CEO increases his holdings of the company’s shares with purchases of over SEK 1 million

Klaria Pharma Holding AB (publ) announces that its CEO Jesper Wiklund has increased his holdings in shares of the company in the previous six months by acquiring 176,984 shares at a cost of 1,015,355 SEK. Additionally, Klaria’s board member Anders Ardstål has acquired 40,000 Klaria shares. 

All board members of Klaria are shareholders in the company. Klaria’s CSO and board member Scott Boyer holds 725,010 shares in the company and board member Björn Littorin owns 72,000 shares. 

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.